Consensus Contineum Therapeutics, Inc.

Equities

CTNM

US21217B1008

Market Closed - Nasdaq Other stock markets 15:59:51 2024-05-30 EDT			5-day change	1st Jan Change
15.23 ^USD	-0.78%		-5.46%	0.00%

05-20	Contineum Therapeutics, Inc. Appoints Troy Ignelzi as Independent Member of Its Board of Directors and as Chair of the Audit Committee	CI
04-30	Morgan Stanley Starts Contineum Therapeutics With Overweight Rating	MT

Evolution of the average Target Price on Contineum Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

ea98ee70ae60cad7a85b3cdf4d66157f._-HcGXbv_DtLrBWlg57hG7uK1z_GKYIgSYdMlkldm04.tdCwLE6bxQ0snyeXz7PWK9Hkgnarf69DMcEYuzw72DyX0JhLEtfFYyn9XA~d56236cf2468c9169b0c41b26ef38281

Analyst Recommendations on Contineum Therapeutics, Inc.

Morgan Stanley Starts Contineum Therapeutics With Overweight Rating	04-30	MT
Stifel Starts Contineum Therapeutics With Buy Rating, $29 Price Target	04-30	MT
RBC Initiates Contineum Therapeutics at Outperform, Speculative Risk With $30 Price Target	04-30	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

15 USD

Average target price

28 USD

Spread / Average Target

+86.67%

High Price Target

30 USD

Spread / Highest target

+100.00%

Low Price Target

25 USD

Spread / Lowest Target

+66.67%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Contineum Therapeutics, Inc.

RBC Capital Markets
Stifel Nicolaus
Morgan Stanley

Quarterly revenue - Rate of surprise

Company calendar